Arrowhead Research Corp. (NASDAQ:ARWR) dropped 4.5% during mid-day trading on Wednesday . The company traded as low as $6.73 and last traded at $6.76, with a volume of 506,499 shares. The stock had previously closed at $7.08.

ARWR has been the subject of a number of analyst reports. Cantor Fitzgerald initiated coverage on Arrowhead Research Corp. in a research note on Wednesday, August 17th. They issued a “buy” rating and a $15.00 price target for the company. William Blair initiated coverage on shares of Arrowhead Research Corp. in a report on Friday, August 19th. They set an “outperform” rating for the company. Piper Jaffray Cos. dropped their price objective on shares of Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating for the company in a report on Wednesday, August 10th. Chardan Capital initiated coverage on shares of Arrowhead Research Corp. in a report on Thursday, May 19th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Jefferies Group reissued a “hold” rating and set a $4.75 price objective on shares of Arrowhead Research Corp. in a report on Wednesday, May 11th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Arrowhead Research Corp. currently has a consensus rating of “Buy” and a consensus price target of $10.44.

The company’s 50-day moving average price is $6.24 and its 200 day moving average price is $5.51. The firm’s market capitalization is $421.00 million.

Arrowhead Research Corp. (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. The business had revenue of $39.58 million for the quarter, compared to analysts’ expectations of $0.05 million. During the same period in the prior year, the company posted ($0.27) EPS. The firm’s revenue was down 68.0% on a year-over-year basis. On average, analysts expect that Arrowhead Research Corp. will post ($1.31) earnings per share for the current year.

In other Arrowhead Research Corp. news, CFO Kenneth Allen Myszkowski sold 6,900 shares of the business’s stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $8.00, for a total value of $55,200.00. Following the transaction, the chief financial officer now directly owns 128,789 shares in the company, valued at approximately $1,030,312. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.